Acinetobacter Infection in the ICU

Clinton K. Murray*, Duane R. Hospenthal

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Acinetobacter is a formidable challenge to managing critically ill patients. This pathogen's ability to rapidly develop antimicrobial resistance to all currently available antimicrobial agents is concerning because increasing data support attributable mortality to these bacteria when associated with hospitalized patients with comorbidities and severe illness. The role of dual therapy is currently unclear and might be associated with increased toxicities without proven synergy or ability to prevent the development of resistance. Infection control and antibiotic control measures might have the greatest impact on these bacteria. Continued efforts are needed to develop new antimicrobial agents against this pathogen and assess the ideal currently available agents.

Original languageEnglish
Pages (from-to)237-248
Number of pages12
JournalCritical Care Clinics
Issue number2
StatePublished - Apr 2008
Externally publishedYes


Dive into the research topics of 'Acinetobacter Infection in the ICU'. Together they form a unique fingerprint.

Cite this